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Mexiletine and tocainide were administered to 79 pa•
tients to determine whether the response to one of these 
drugs would predict the effect of the other. In 57 pa•
tients, the two agents were evaluated noninvasively with 
monitoring and exercise testing, and efficacy was judged 
by the suppression of spontaneous ventricular arrhyth•
mia. In the remaining 22 patients, electrophysiologic 
testing was performed and efficacy was defined as the 
inability to induce more than two repetitive ventricular 
premature beats. An equal number of patients re-
Available antiarrhythmic drugs do not possess distinctive 
electrophysiologic properties that help predict their clinical 
action. Selection of an effective drug demands individual 
evaluation of each agent. This is a time-consuming and 
costly undertaking. Therapy would be simplified if response 
to a particular drug could be reliably and expeditiously de•
termined. It has been proposed that drugs with shared elec•
trophysiologic properties in vitro may be grouped together 
(1). Such a classification of drugs implies that all the mem•
bers of a group have c commonality of clinical effects on 
arrhythmia and can be used interchangeably. Indeed, it has 
been reported that a favorable effect obtained with procain•
amide predicts a like response to quinidine, disopyramide, 
lidocaine and phenytoin (2). 
Tocainide and mexiletine are congeners of lidocaine with 
similar chemical structures and identical in vitro and in vivo 
electrophysiologic properties (3,4). Although both drugs 
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sponded to mexiletine and tocainide (38 versus 39%). 
However, in only 42 patients (53 %) were the results 
concordant. There was no difference in concordance when 
the results were analyzed by method of drug evaluation, 
left ventricular ejection fraction or etiology of presenting 
arrhythmia. It is concluded that mexiletine and tocainide 
have different clinical effects and must be evaluated 
individually. 
(J Am Coli CardioI1986;7:338-43) 
have been reported to be effective for the treatment of ven•
tricular arrhythmias (5-8), no studies have compared the 
action of these two drugs in the same group of patients. 
The purpose of this study was to determine whether one of 
these drugs predicts the response to the other. 
Methods 
Study patients. Seventy-nine consecutive patients, re•
ferred for the management of life-threatening ventricular 
arrhythmias, were studied. The group consisted of 64 men 
and 15 women with a mean age of 56 years (range 23 to 
79). Cardiac diagnoses included coronary artery disease in 
53 patients, cardiomyopathy in 9 and valvular heart disease 
in 8. Nine patients had no structural heart disease as judged 
by cardiac catheterization and echocardiographic findings. 
The presenting arrhythmia was ventricular fibrillation in 
24 patients and ventricular tachycardia in 55 patients. In 41 
of the latter 55 patients the tachycardia was sustained and 
associated with either syncope or presyncope. Nonsustained 
ventricular tachycardia associated with dizziness was the 
presenting arrhythmia in 14 of the 55 patients. In no case 
was the arrhythmia a consequence of acute myocardial in•
farction or another reversible condition. In each patient pre•
vious therapy with conventional drugs, including quinidine, 
procainamide, disopyramide and a beta-receptor blocker, 
was either not tolerated because of side effects or was in•
effective despite blood levels in the defined therapeutic range. 
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Baseline evaluation. On hospital admission all antiar•
rhythmic agents were discontinued and patients were con•
tinuously monitored by telemetry (CAMS, American Op•
tical) (9,10). Digoxin and diuretic drugs were continued for 
control of congestive heart failure. Antianginal medications 
were not altered during drug evaluation. After a washout 
period of at least 36 hours, patients underwent 48 hours of 
continuous ambulatory monitoring (II) and a maximal 
symptom-limited exercise tolerance test performed on a mo•
torized treadmill in accordance with the Bruce protocol (12). 
This constituted the control period. in which the frequency, 
type and reproducibility of spontaneous arrhythmia were 
evaluated. 
Ventricular arrhythmia was categorized by the Lown 
grading system (13): grade 0, no ventricular premature beats; 
grade IA. fewer than 30 ventricular premature beats/h and 
less than I/min; grade lB. fewer than 30 ventricular pre•
mature beats/h and occasionally more than I/min; grade 2, 
more than 30 ventricular premature beats/h; grade 3, mul•
tiform ventricular premature beats; grade 4A. repetitive ven•
tricular premature beats. couplets; grade 4B, repetitive ven•
tricular premature beats. runs of ventricular tachycardia (2:3 
cycles); and grade 5, early R on T ventricular premature 
beats. 
A noninvasive approach was used to evaluate drug effect 
if the following arrhythmia was reproducibly present each 
day: on ambulatory electrocardiographic monitoring. grade 
2 ventricular premature beats for more than 50% of the hours 
in association with grade 4 arrhythmia for at least 3 hours. 
and with exercise testing, ventricular premature beats at a 
rate of at least 2/min in association with grade 4 arrhythmia. 
Twenty-two patients with low frequency or nonreproducible 
arrhythmia during control monitoring and exercise testing 
underwent baseline electrophysiologic testing using pro•
grammed electrical stimulation (14). 
Electrophysiologic testing. A 6F USCI hexapolar elec•
trode catheter was inserted by way of the left subclavian 
vein under fluoroscopic guidance and positioned in the right 
ventricular apex. One, two or three extrastimuli were se•
quentially added during both sinus and ventricular paced 
rhythms at a cycle length of 500 ms. The current strengths 
of extrastimuli were two and three times the mid-diastolic 
threshold. The number of stimuli utilized was increased until 
an end point was induced. The end point for testing was 
nonsustained or sustained ventricular tachycardia that re•
sembled the clinical arrhythmia. Nonsustained ventricular 
tachycardia was defined as three or more repetitive responses 
lasting up to 30 seconds, while sustained ventricular tachy•
cardia was defined as an arrhythmia persisting for more than 
30 seconds. We (14) and other investigators (15-17) have 
used non sustained ventricular tachycardia as an end point 
for drug selection as distinct from the use of this technique 
to predict risk. 
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Table 1. Results of Therapy in the 79 Study Patients* 
Noninvasive Therapy InvaSIve Therapy 
(n = 57) (n = 22) 
Overall 
Ineffecttve EffectIve Ineffecttve Effecttve Efficacy 
Mextletlne 36 21 (37%) 13 9 (42%) 30 (38%) 
Tocalnlde 33 24 (47%) 15 7 (32%) 31 (39%) 
*Monitoring and exercIse testing were used to evaluate drug response 
In 57 patIents while invasive electrophy,iology was employed in 22. Over•
all. each drug was effectIve In 389< of patIents and Its effect was not related 
to the method of evaluation 
Drug therapy. At the conclusion of control studies 
therapy with either tocainide or mexiletine was initiated i~ 
the following manner for those undergoing a noninvasive 
protocol. The oral dose of tocainide was 400 mg and that 
of mexiletine was 200 mg; each was administered three 
times daily. Daily dosage was increased every 24 hours if 
the arrhythmia persisted and no adverse effects supervened. 
The. ~aximal daily dose administered was 2,400 mg of 
tocalmde and 1,200 mg of mexiletine. After at least 4 days 
of therapy, ambulatory electrocardiographic monitoring and 
exercise testing were repeated. Criteria for drug efficacy 
during monitoring and exercise testing included the follow•
ing: I) a greater than 90% reduction in the frequency of 
ventricular tachycardia (grade 4B) and couplets (grade 4A), 
and 2) a greater than 50% decrease in grade 2 ventricular 
premature beats. For a drug to be judged effective with 
noninvasive evaluation. both monitoring and exercise cri•
teria for efficacy had to be met. 
Drug dosing in patients undergoing electrophysiologic 
testing followed a similar schedule to that outlined, and the 
dose was titrated on the basis of side effects. After 4 days 
of therapy with one agent, electrophysiologic studies were 
repeated. The criterion for efficacy by this method was 
inability to provoke three or more repetitive responses dur•
ing sinus rhythm and ventricular pacing after administration 
of three sequential extrastimuli. We (14) have previously 
reported the use of this end point for defining drug efficacy. 
Because it is not certain that conversion of sustained to 
Table 2. Correlation Between Response to Mexiletine and 
Tocainide in the 79 Study Patients 
Mexiletine 
Effecttve Ineffective 
Tocainide 
Effecttve 12 19 
Ineffecti ve 18 30 
Total 30 49 
Total 
31 
48 
79 
Concordance = 42 (53%) of 79. dIscordance = 37 (47%) of 79; p 
= NS. 
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nonsustained ventricular tachycardia represents a drug re•
sponse, we used a more rigorous criterion for drug efficacy. 
Blood/or drug levels was obtained 2 hours after dosing, 
at the time the exercise test or electrophysiologic study was 
performed. At the conclusion of evaluation with one drug, 
a 24 hour washout period intervened before the second agent 
was initiated. The dose was titrated as described earlier. 
Patients received the drugs in no consistent order. 
Statistical analysis was performed by the chi-square 
method. The criterion for significance was probability (p) 
less than 0.05. 
Results 
Tocainide and mexiletine were equally effective in the 
79 patients. Mexiletine was effective in 30 patients (38%) 
and tocainide in 31 (39%) (Table 1). Patients who did not 
respond showed no significant change in the frequency of 
ventricular premature beats or repetitive forms. In patients 
whose arrhythmia remained inducible during electrophysi•
ologic testing, the same end point was induced and cycle 
length was not significantly altered. Both drugs were ef•
fective in 12 patients (15%) and ineffective in 30 patients 
(38%). Thus the results of therapy with the two agents were 
concordant in 42 (53%) of the 79 patients (Table 2). In 19 
patients only tocainide was effective while in 18 only mex•
iletine suppressed arrhythmia. Blood levels did not distin•
guish responders from nonresponders; with mexiletine the 
respective values were 1.8 and 1.9 JLg/ml and with tocainide 
they were 9.1 and 8.8 JLg/ml. 
Noninvasive versus invasive findings. Of the 57 pa•
tients who underwent noninvasive testing, 52% had a con•
cordant result. When the responses during ambulatory mon•
itoring and exercise testing were evaluated independently, 
Table 3. Response to Drugs Based on Method of Evaluation 
Mexiletine 
Effeclive Ineffective Total 
Noninvasive* 
Tocainide 
Effective 9 15 24 
Ineffective 12 21 33 
Total 21 36 57 
Invasivet 
Tocainide 
Effective 3 4 7 
Ineffective 6 9 15 
Total 9 13 22 
*Concordance for noninvasive testmg = 30 (52%) of 57, discordance 
= 27 (47%) of 57; P = NS. tConcordance for invasive testing = 12 
(55%) of 22, discordance = 10 (45%) of 22; p = NS. 
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Table 4. Relation Between Presenting Arrhythmia and 
Response to Drug 
Mexiletine 
Effeclive Ineffeclive 
Ventricular Tachycardia (n = 55)* 
Tocainide 
Effective 9 12 
Ineffeclive 12 22 
Total 21 34 
Ventricular Fibrillation (n = 24)t 
Tocainide 
Effective 3 7 
Ineffective 6 8 
Total 9 15 
Total 
21 
34 
55 
10 
14 
24 
*Concordance for ventricular tachycardia = 31 (56%) of 55, discor•
dance = 24 (44%) of 55. tConcordance for ventricular fibrillation = 11 
(46%) of 24, discordance = 13 (54%) of 24. 
concordance was the same. This was similar to the 55% 
concordance encountered in the 22 patients subjected to 
electrophysiologic studies (Table 3). There was no differ•
ence in concordance when test results were analyzed by end 
point achieved, that is, sustained or nonsustained ventricular 
tachycardia. The method of drug evaluation--:noninvasive 
or invasive studies-was not helpful in predicting response 
to either tocainide or mexiletine. Analysis based on the 
etiology of the presenting arrhythmia, whether nonsustained 
or sustained ventricular tachycardia, similarly failed to im•
prove the degree of concordance (Table 4). 
Ejection fraction. Left ventricular ejection fraction was 
assessed in 62 patients by either contrast or radionuclide 
angiography and was greater than 40% (mean 55%) in 24 
Table 5. Relation Between Left Ventricular Ejection Fraction 
(EF) and Drug Response 
Mexiletine 
Effective Ineffeclive Total 
EF <40% (average 25%)* 
Tocainide 
Effective 3 8 11 
Ineffective 8 19 27 
Total 11 27 38 
EF >40% (average 55%)t 
Tocainide 
Effective 5 7 12 
Ineffective 6 6 12 
Total 11 13 24 
*Concordance for EF <40% = 22 (58%) of 38, discordance = 16 
(42%) of 38; p = NS. tConcordance for EF >40% = II (46%) of 24, 
discordance = 13 (54%) of 24; p = NS. 
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patients and less than 40% (mean 25%) in 38 patients. In 
46% of patients with an ejection fraction greater than 40%, 
the tocainide and mexiletine responses were concordant, 
whereas they were concordant in 58% of patients with an 
ejection fraction of less than 40% (Table 5), Tocainide and 
mexiletine were of equal efficacy irrespective of the ejection 
fraction. However, greater efficacy of both drugs was ob•
served in patients with an ejection fraction greater than 40% 
(p < 0.05) (Table 6). Mexiletine was effective in II (46%) 
of 24 patients with a left ventricular ejection fraction greater 
than 40% and tocainide was effective in 12 (50%) of 24 
such patients. In contrast, when ejection fraction was less 
than 40%, the drugs were effective in II (29%) of 38. 
Discussion 
Therapy for ventricular arrhythmia is empiric, without 
practical clinical guidelines for predicting drug response. 
Although there is controversy about how to evaluate drug 
efficacy, it has been reported (10,18) that therapy with an•
tiarrhythmic drugs will prevent recurrent tachyarrhythmia 
when spontaneous arrhythmia is suppressed or induced ar•
rhythmia cannot be provoked. However, establishing an 
effective drug program is a time-consuming and costly pro•
cess. The ability to predict with certainty the effectiveness 
of a particular drug would improve the process of drug 
selection, 
Mexiletine versus tocainide. Classifying antiar•
rhythmic drugs on the basis of their electrophysiologic prop•
erties is a widely accepted practice (1). The assumption is 
that drugs with similar electrophysiologic actions may have 
similar clinical antiarrhythmic effects. Mexiletine and to•
cainide are ideal candidates to support this hypothesis. They 
are both lidocaine congeners and structurally resemble each 
other. As membrane stabilizing agents, classified as I B 
drugs, they decrease membrane conductivity and shorten 
action potential duration. They have little effect on the re•
fractory period; however, the ratio of refractory period to 
action potential duration is increased, resulting in a reduc•
tion of membrane excitability. They share similar phar-
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macologic properties and cause the same type of toxicity, 
In this study, tocainide and mexiletine were equally effective 
in a group of patients with refractory sustained ventricular 
tachyarrhythmias. Surprisingly, the response to these two 
agents was similar in only 53% of patients. Analysis based 
on method of evaluating drug effect on presenting arrhyth•
mia or left ventricular function did not improve the con•
cordance. Concordance of response tended to be greater in 
patients with a left ventricular ejection fraction of less than 
40% than in patients with an ejection fraction greater than 
40% (58 versus 46%), but this difference was not statisti•
cally significant. This result was largely due to the fact that 
in patients with a decreased left ventricular ejection fraction 
both drugs were more often ineffective than they were in 
patients with a higher ejection fraction. Mexiletine and to•
cainide are therefore clinically different from each other and 
the antiarrhythmic effect of one drug is not predicted by the 
response to the other. Each drug must be evaluated 
individually. 
Concordance of response between related antiar•
rhythmic agents. Only a few studies have reported cor•
relation of response to related agents, and their results are 
conflicting, Waxman et a1. (2) reported that the response to 
intravenous procainamide predicted the response to other 
membrane-active agents of the same class, specifically quin•
idine, disopyramide, lidocaine and phenytoin. Twenty-five 
(83%) of 30 patients whose arrhythmia was non inducible 
when receiving intravenous procainamide responded to at 
least one other drug. These 30 patients underwent 67 drug 
studies and in 43 studies (64%) the drug was effective. In 
contrast, 69 patients unresponsive to procainamide under•
went 145 drug studies. In only nine patients (13%) and in 
10 studies (7%) was another agent effective. The authors 
concluded that failure to respond to intravenous procain•
amide eliminated the need to evaluate other conventional 
agents. There are a number of inadequacies in this retro•
spective study. Drug levels were available in only a minority 
of patients. As reported, disopyramide blood levels were 
significantly lower in nonresponders than in responders 
(p = 0.01). An additional limitation was that lidocaine, 
quinidine, disopyramide and phenytoin were not evaluated 
Table 6. Relation Between Presenting Arrhythmia, Left Ventricular Function 
and Drug Response 
Mexiletine Tocainide Responders to Nonresponders 
Presentmg Responders Responders Both Drugs to Both Drugs Concordance 
Arrhythmia LVEF No (O/C) (%) (%) (o/c) (%) 
Ventncular ~40% 16 8 (50) 8 (50) ..\ (25) 4 (25) 8 of 16 (50) 
tachycardia <40% 26 7 (27) 8 (31) 3 (\2) 14 (54) 17 of 26 (65) 
(n = 42) 
Ventncular ~40% 8 3 (38) 4 (50) I (\3) 2 (25) 3 of 8 (38) 
fibrillation <40% 12 4 (33) 3 (25) 0 5 (42) 5 of 12 (42) 
(n = 20) 
L VEF = left ventncular ejectIon fractIon 
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in all patients receiving procainamide. The responses to all 
drugs and drug combinations were combined and then com•
pared with response to procainamide using a simple chi•
square test. Had the response to each drug been compared 
with the response to procainamide, the results would have 
been more conclusive, but there might have been a loss of 
predictive value because of inadequate sample size. 
Other investigators have reported different results (19-21). 
Oseran et al. (19) noted that of 11 patients whose arrhythmia 
remained inducible during administration of intravenous 
procainamide. 6 responded to oral procainamide or oral 
quinidine. Thus, intravenous procainamide was predictive 
in only 45% of patients. Wyse et al. (20) noted that pro•
cainamide did not predict the response to quinidine or di•
sopyramide in 6 (26%) of 23 patients. In a group of 98 
patients, Rae et al. (22) reported that failure to respond to 
procainamide did not predict response to other agents. The 
lack of concordance in antiarrhythmic efficacy among quin•
idine, procainamide and disopyramide might be explained 
by their dissimilar chemical structures. When two very sim•
ilar drugs such as lidocaine and tocainide are compared. 
concordance is improved but does not accurately predict 
drug effectiveness in all patients. 
In our previous experience (5) with a group of 50 patients 
treated with both of these agents in random sequence. lid•
ocaine predicted tocainide response in 78%. However, a 
negative response to lidocaine was more helpful than a pos•
itive response. Of 27 patients who failed to respond to 
lidocaine. 23 (85%) did not respond to tocainide. In contrast. 
of the 14 patients responding to lidocaine. 12 (63%) also 
responded to tocainide. Similar results were reported by 
Winkle et al. (23) in a group of 26 patients. 
Factors affecting concordance of drug response. In 
studying the concordance rates of two antiarrhythmic drugs, 
one must be attentive to the prevalence of severe heart 
disease in the population sample. If the sample is skewed 
owing to a preponderance of patients with markedly im•
paired ventricular dysfunction, a spuriously high concord•
ance rate will be observed, in part because antiarrhythmic 
drug efficacy is reduced in patients with substantial myo•
cardial compromise. In the present study, drug effectiveness 
was directly related and the concordance rate inversely re•
lated to ejection fraction. Among patients with ventricular 
tachycardia and an ejection fraction greater than 40%, the 
response to either mexiletine or tocainide was 50% and the 
concordance for the two drugs was also 50%; however, in 
those with an ejection fraction of less than 40%, efficacy 
of either agent was approximately 30% whereas concord•
ance was 65%. 
Classification of antiarrhythmic drugs is based on their 
electrophysiologic properties, but clinical effects may differ. 
The reason for this is not clear but may be due to differences 
in tissue binding, metabolism, clearance and effects of me•
tabolites. Even structurally identical agents, which are only 
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stereometric ally different, possess markedly different prop•
erties, Such is the case with D-propranoloL and L-propran-
0101 and quinidine and quinine, Thus. in any patient. the 
effect of an antiarrhythmic drug is unpredictable. 
Conclusions. In this study we have demonstrated that 
mexiletine and tocainide are both effective antiarrhythmic 
agents, However. the response to one of these drugs will 
not predict the effect of the other. Therefore. these agents 
have different clinical effects and each must be evaluated 
individually, 
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